Introduction
============

Prednisolone is a synthetic glucocorticoid that has been used over the last few decades as pharmacotherapy in a plethora of diseases due to its potent antiinflammatory and immunosuppressive properties ([@bib1]). Prednisolone is absorbed rapidly after oral intake, reaching peak plasma levels within the first hour after ingestion ([@bib2]). The mean plasma half-life is 2--4 h ([@bib3], [@bib4]); metabolism occurs predominantly in the liver ([@bib5]) but also via the actions of renal 11β-hydroxysteroid dehydrogenase type 2 converting it into the inactive metabolite prednisone ([@bib6]). Inter-individual differences in the rate of metabolism of prednisolone result in variable metabolic clearance rates, which in part, may explain the observed differences in the development of corticosteroid side effects between patients ([@bib7]).

Interestingly, when the endogenous glucocorticoid, cortisol (hydrocortisone), is compared with prednisolone at the isolated human glucocorticoid receptor (GR), the transactivation activity of prednisolone is 1.7-fold higher than that of hydrocortisone ([@bib8], [@bib9]). However, the biological effect of prednisolone is usually represented as 4-fold that of hydrocortisone. This observation is derived from experiments in humans investigating the dose necessary to induce negative feedback on adrenocorticotropic hormone (ACTH) secretion in hypothalamic--pituitary axis regulation ([@bib10]). The discrepancy between pure receptor binding and the biological effect might be explained in part by the fact that prednisolone displays only 50% of the affinity of cortisol for corticosteroid-binding globulin ([@bib11]), resulting in relatively higher concentrations of free, unbound prednisolone. In addition, prednisolone has a higher re-activation rate from prednisone to prednisolone by hepatic 11β-hydroxysteroid dehydrogenase type-1, which is approximately 3-fold greater than that for cortisone to cortisol ([@bib6]). This might explain the observation that orally administered prednisone shows more effective hepatic activation than cortisone, resulting in higher systemic availability of the active 11β-hydroxy form, prednisolone ([@bib12]).

Prednisolone is used in some patients with adrenal insufficiency (AI) as hormone replacement therapy. Advocates of prednisolone highlight that it requires only once-daily administration, resulting in improved compliance and that it is highly cost-effective ([@bib13]). In some cases, it has been used where hydrocortisone is not available (e.g., historically in the former German Democratic Republic).

In the recent Endocrine Society Clinical Practice guideline summarising therapy in AI ([@bib14]), prednisolone (3--5 mg/day) is suggested as an alternative to hydrocortisone, particularly in patients with reduced compliance; however, currently, prospective studies comparing the safety and efficacy of prednisolone and hydrocortisone over time are not available. A recent review on AI stated that prednisolone should only be considered in the event of compliance problems, marked fluctuations of energy and when hydrocortisone or cortisone acetate is not tolerated ([@bib15]).

As indicated by the very low level of evidence in the recent guideline, data on prednisolone in hormone replacement therapy are scarce ([@bib16], [@bib17], [@bib18], [@bib19]), with no available data regarding the effects on cardiovascular risk factors. Data from patients with rheumatoid arthritis on low-dose prednisolone/prednisone (defined as a dose of prednisone \<10 mg/day) suggest a trend of increasing cardiovascular events ([@bib20]).

Using data derived from the European Adrenal Insufficiency Registry (EU-AIR), we investigated relative differences in cardiovascular risk factors in patients with AI receiving hydrocortisone and prednisolone as hormone replacement therapy.

Methods
=======

Study design
------------

EU-AIR is an observational, open-ended study (ClinicalTrials.gov identifier: Nbib1661387) in patients with primary AI (PAI), secondary AI (SAI) or congenital adrenal hyperplasia (CAH) who are undergoing long-term treatment with modified-release hydrocortisone or other glucocorticoid replacement therapies ([@bib21]). The primary objective of the EU-AIR is to monitor the safety of long-term treatment with once-daily modified-release hydrocortisone and other glucocorticoid replacement therapies in patients with AI.

All enrolled patients provided written informed consent/assent. The study protocol was approved by the appropriate ethical committee in each country. Data were collected from endocrinology centres in Germany, the Netherlands, Sweden and the UK. All enrolled patients were followed during the course of routine clinical practice for the active duration of the registry. All medical care decisions, including those relating to treatment choice, are entirely at the discretion of the patient and registry physician. Patient data, including laboratory assessments, were collected by means of an electronic case report form at enrolment and thereafter at routine clinic visits (every 6--12 months) ([@bib21]).

Recruitment began in August 2012; as of May 2015, 1166 patients have been enrolled. Patients with CAH and those receiving modified-release hydrocortisone were not included in the current analysis. Exposure records with a duration of less than 28 days were excluded to ensure that treatment at baseline was not related to emergency/temporary use of medication.

Patients were grouped according to whether they had received prednisolone or hydrocortisone. To define the prednisolone group, we excluded patients receiving glucocorticoids other than prednisolone. In the hydrocortisone group, we excluded patients receiving glucocorticoids other than hydrocortisone and those receiving dual-release hydrocortisone.

Matched analysis
----------------

Patients receiving prednisolone at doses \<3 mg/day and \>6 mg/day in the prednisolone group were excluded from the matched analysis, thus including only those patients on doses of 3--6 mg/day, as recently recommended by the Endocrine Society guideline ([@bib14]). Furthermore, patients receiving hydrocortisone at doses \<15 mg/day and \>30 mg/day in the hydrocortisone group were excluded, thus including only those patients receiving recommended daily doses that are also most frequently prescribed ([@bib14]). These criteria identified 50 patients in the prednisolone group and 909 patients in the hydrocortisone group.

Patients receiving prednisolone and hydrocortisone were matched on estimated propensity scores ([@bib22]) using greedy matching algorithm to find the nearest available match in a 1:3 ratio for age, gender, duration and type of disease (SAI or PAI). The resultant cohort consisted of 47 patients receiving prednisolone matched to 141 patients on hydrocortisone. The following variables were measured after matching: daily dose of glucocorticoid; body mass index; systolic and diastolic blood pressure; waist circumference; total cholesterol; high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol; glycated haemoglobin (HbA1c); triglycerides and the proportion of patients using statins.

Statistics
----------

Summary statistics of continuous data and frequency counts (proportions) of categorical data were generated before and after matching to evaluate the closeness of matching. Cardiovascular risk factors between prednisolone and hydrocortisone groups were summarised using summary statistics and compared using an appropriate two-sample *t*-test at a 5% level of significance.

Follow-up data
--------------

Data were available for 109 out of 147 patients in the hydrocortisone group at the follow-up visit (10.0 ± 4.9 months); all these patients continued with hydrocortisone as hormone replacement therapy. Overall, 39 out of 41 patients in the prednisolone group were still on prednisolone as hormone replacement therapy and had data available at their follow-up visit (6.9 ± 2.9 months).

Results
=======

We identified 64 patients with PAI and SAI who received prednisolone as hormone replacement therapy. Baseline characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Based on the records of prednisolone use, daily doses ranged from \<2 to \>7.5 mg ([Fig. 1](#fig1){ref-type="fig"}). The dose range received by the most patients was 5--\<6 mg/day, which was being taken by 57.8% of patients at baseline ([Fig. 1](#fig1){ref-type="fig"}). Overall, 20.3% of patients on prednisolone took a daily dose of 6 mg or higher. Prednisolone was being taken once-daily by 73.4% of patients and twice-daily by 25.0% ([Fig. 2](#fig2){ref-type="fig"}). Figure 1Daily doses of prednisolone as hormone replacement therapy in patients with primary and secondary adrenal insufficiency from the EU-AIR (*n* = 64). Patients with congenital adrenal hyperplasia were excluded. EU-AIR, European Adrenal Insufficiency Registry. Figure 2Frequency of prednisolone daily doses in hormone replacement therapy of patients with primary and secondary adrenal insufficiency from the EU-AIR (*n* = 64). Patients with congenital adrenal hyperplasia were excluded. EU-AIR, European Adrenal Insufficiency Registry. Table 1Baseline characteristics of patients with PAI and SAI from the EU-AIR (*n* = 64) receiving prednisolone as hormone replacement therapy.**ParameterAnalysis population** (*n* = 64)Age (years)58.3 (±16.7)Duration of disease (years)25.0 (±13.1)Female, *n* (%)40 (62.5)Body mass index category, *n* (%) Normal (18.5--\<25 kg/m^2^)18 (28.1) Overweight (25--\<30 kg/m^2^)29 (45.3) Obese (≥30 kg/m^2^)15 (23.4)Missing data2 (3.1)Total cholesterol (mmol/L)6.26 (±1.49)Low-density lipoprotein cholesterol (mmol/L)3.85 (±1.27)Systolic blood pressure (mmHg)130 ± 18Diastolic blood pressure (mmHg)78 ± 9[^1][^2][^3]

After predefining the matching cohorts, we performed a 1:3 matching of patients on prednisolone replacement therapy to patients on hydrocortisone therapy regarding sex, age, duration and type of disease ([Table 2](#tbl2){ref-type="table"}). Table 2Cohorts of patients with AI from the EU-AIR with prednisolone or hydrocortisone replacement therapy used for the matching process (for age, sex, duration and type of disease (PAI or SAI)).**Before matchingAfter matchingVariable**Prednisolone (*n* = 50)Hydrocortisone (*n* = 909)Prednisolone (*n* = 47)Hydrocortisone (*n* = 141)Age (years)58.5 (16.6)54.2 (16.2)58.0 (16.6)60.0 (14.4)Duration of disease (years)25.1 (13.6)15.4 (11.0)23.0 (10.3)23.1 (10.2)Female (%)62.050.861.761.7PAI (%)40.030.940.440.4[^4][^5]

The frequency of diagnosis of hypertension and diabetes mellitus was not significantly different between the two matched cohorts ([Table 3](#tbl3){ref-type="table"}). Further analysis revealed no significant differences in body mass index (BMI) and systolic or diastolic blood pressure ([Table 4](#tbl4){ref-type="table"}). There was a tendency for waist circumference to be greater in prednisolone-treated patients, but this did not reach statistical significance. After analysing the biochemical characteristics of the two matched cohorts, we found significantly higher total cholesterol (*P* = 0.003) and LDL cholesterol levels (*P* = 0.013) in patients receiving prednisolone vs those receiving hydrocortisone ([Table 4](#tbl4){ref-type="table"}). The difference in total cholesterol was significant in patients with primary and secondary AI; the difference in LDL cholesterol was significant in patients with primary AI only ([Supplementary Table 1a and 1b](http://www.endocrineconnections.org/cgi/content/full/EC-16-0081/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article). Statins were not prescribed in significantly different proportions in the two cohorts ([Table 4](#tbl4){ref-type="table"}). Table 3Frequency of diagnoses in matched cohorts of patients with AI from the EU-AIR with prednisolone or hydrocortisone replacement therapy.**After matchingDiagnosis** (%)**Prednisolone** (*n* = 47)**Hydrocortisone** (*n* = 141)Hypertension36.235.5Diabetes mellitus, all14.914.9Diabetes mellitus type 14.30.0Diabetes mellitus type 210.614.9[^6] Table 4Clinical and biochemical characteristics in matched cohorts of patients with AI from the EU-AIR with prednisolone or hydrocortisone replacement therapy.**After matchingVariablePrednisolone** (*n* = 47)**Hydrocortisone** (*n* = 141)Daily dose (mg)5.0 (0.6)21.5 (4.8)Body mass index (kg/m^2^)27.2 (3.9) (*n* = 44)27.8 (5.3) (*n* = 119)Systolic blood pressure (mmHg)128 (18.1) (*n* = 47)131 (18.0) (*n* = 133)Diastolic blood pressure (mmHg)77.7 (9.2) (*n* = 47)79.4 (10.2) (*n* = 133)Waist circumference (cm)99.0 (13.8) (*n* = 21)96.1 (13.9) (*n* = 86)Total cholesterol (mmol/L)6.3 (1.6)\*\*\* (*n* = 36)5.4 (1.1) (*n* = 82)High-density lipoprotein (mmol/L)1.5 (0.5) (*n* = 31)1.5 (0.4) (*n* = 76)Low-density lipoprotein (mmol/L)3.9 (1.4)\*\* (*n* = 34)3.2 (1.0) (*n* = 71)HbA1c (%)5.8 (1.0) (*n* = 32)5.8 (1.0) (*n* = 81)Triglycerides (mmol/L)1.8 (0.8) (*n* = 35)1.9 (0.9) (*n* = 82)Proportion of patients using statins (%)25.526.9[^7][^8][^9]

No significant differences were seen regarding HbA1c, HDL cholesterol and triglyceride levels. After stratifying for gender, we observed significantly higher total and LDL cholesterol levels in prednisolone-treated vs hydrocortisone-treated women. Total cholesterol levels were significantly higher in prednisolone-treated vs hydrocortisone-treated men; the trend for LDL cholesterol failed to reach statistical significance (*P* = 0.179; data not shown).

At follow-up visits, patients on hydrocortisone still showed significantly lower total and LDL cholesterol levels than those receiving prednisolone (total cholesterol: 5.3 ± 1.1 vs 6.0 ± 1.3 mmol/L, *P* = 0.005; LDL cholesterol: 3.1 ± 1.0 vs 3.8 ± 1.2 mmol/L, *P* = 0.006).

Discussion
==========

Cardiovascular disease is the major cause of mortality in the majority of developed countries ([@bib23]). It is therefore important to identify patients with increased cardiovascular risk who would benefit from initiation of risk-reducing interventions. The well-established major vascular risk factors are age, sex, hypertension, smoking, dyslipidaemia and diabetes mellitus ([@bib24]).

Recent retrospective epidemiological data indicate high mortality among patients with both PAI and SAI ([@bib25], [@bib26], [@bib27], [@bib28]). Besides adrenal crisis ([@bib29]) and infectious disease ([@bib26]), cardiovascular disease shows a 2-fold increased risk for mortality in Swedish patients with PAI compared with the Swedish background population ([@bib26]) and was the main cause for excess mortality in Norwegian patients with PAI ([@bib28]). Cardiovascular disease has also been implicated as the primary cause for increased mortality in SAI ([@bib30]). Several studies have suggested that increased vascular risk might be dependent on the daily hydrocortisone dose ([@bib31], [@bib32]) and the non-physiological daily profile of current glucocorticoid replacement therapy.

Comparisons between different hormone replacement regimens regarding mortality, morbidity or cardiovascular risk factors are scarce at best or even absent. Prednisolone is believed to be cost effective and efficacious, as well as requiring only once-daily administration when used for glucocorticoid replacement therapy in AI ([@bib13]). Recent data, however, suggest that prednisolone is deleterious for bone mineral density in AI ([@bib17], [@bib19], [@bib33], [@bib34]). Few comparative data with hydrocortisone for additional steroid-dependent end points are available. Therefore, we believed that it was important to examine surrogates of vascular risk in patients with AI on prednisolone or hydrocortisone replacement therapy. This study is the first of its kind to investigate this important aspect of glucocorticoid replacement. We showed clearly that prednisolone leads to an adverse lipid profile with increased total and LDL cholesterol levels. The significantly higher LDL levels in patients with AI treated with prednisolone vs those treated with hydrocortisone would predict a relative risk of 1.8 for cardiovascular disease compared with 1.3 for those patients on hydrocortisone in our cohort ([@bib35], [@bib36], [@bib37]).

The only similar data concerning lipid profiles in AI derive from 2424 hypopituitary patients within the KIMS database (a Pfizer International Metabolic database), prior to glucocorticoid hormone substitution ([@bib18]). In that study, 1186 patients were receiving hydrocortisone (mean dose of 24.1 mg/day), and 52 patients were receiving prednisolone (mean dose of 6.7 mg/day). BMI did not differ between the two groups; however, waist-to-hip ratio was increased in the prednisolone group. HDL and LDL cholesterol did not differ among the two cohorts ([@bib18]). No matching, however, was performed in that study, which might explain the difference compared with our observations. In the Filipsson study ([@bib18]), the prednisolone cohort was older than the hydrocortisone group, and gender distribution between study groups was not equal.

Further data regarding prednisolone and cardio­vascular risk are derived only from studies with patients with rheumatoid arthritis, who generally receive higher doses of prednisolone than those used in this study (\>7.5 mg/day). A recent systematic literature review on cardiovascular risk induced by low-dose corticosteroids (defined as a dose of prednisone \<10 mg/day) in rheumatoid arthritis found an association with major cardiovascular events in 4 of 6 studies; two studies did not find any significant association ([@bib20]). Very recently, a 2-year open, randomised trial found a 3.7-fold increased relative risk for cerebrovascular events in patients with early rheumatoid arthritis receiving low-dose prednisolone treatment ([@bib38]). However, drawing a parallel between patients with rheumatoid arthritis on prednisolone and patients with AI on prednisolone may not be valid, especially as patients with active inflammatory arthritis may have other factors that are aberrant, which may increase the risk of cardiovascular events.

In recent years, there has been improved understanding of how glucocorticoids bind to the GR and induce genomic and non-genomic effects. Genomic effects of activated GRs occur after nuclear translocation and manifest through three primary mechanisms: direct binding of GR to DNA via GR response elements and negative GR response elements to activate or repress transcription; tethering to DNA-bound transcription factors to modulate transcription indirectly; or composite activity of DNA binding and interaction with adjacent DNA-bound transcription factors to affect transcription ([@bib39], [@bib40]). Rapid non-genomic effects of GR ligation occur after ligand-induced dissociation of the GR multiprotein complex in the cytoplasm ([@bib39]). This diversity of regulatory processes indicates that prednisolone is likely to regulate different genes than the physiological glucocorticoid, hydrocortisone ([@bib41]).

This implies that the differences between the physiological effects of prednisolone and hydrocortisone do not relate simply to differences in dose equivalence. As outlined earlier, the relative biological potency and conversion rate of hydrocortisone and prednisolone were calculated using the ACTH-suppressive effect ([@bib10]), resulting in a 1:4 conversion rate. However, the effects of prednisolone on eosinophils result in a conversion rate of 6:1 compared with hydrocortisone ([@bib42]) and effects on growth in children with CAH result in a suggested conversion rate of 6--8:1 ([@bib43]). Furthermore, prednisolone causes an increase in urinary nitrogen excretion and a negative nitrogen balance that was reportedly 10--17 times higher than that of hydrocortisone ([@bib42]). Therefore, we believe that there is no unique whole body conversion rate between prednisolone and hydrocortisone but that this relationship is organ specific.

There are some limitations to our study, as observed in all registry based data, e.g. missing data values. The numbers of patients receiving prednisolone was relatively small; however, these numbers constitute the largest cohort of prednisolone-treated patients with AI to date.

A strength of this study is the large number of patients receiving hydrocortisone, which allowed close matching for multiple confounders between the two study cohorts. Another strength of our study is that we could provide follow-up data (via a longitudinal study) and we were able to observe the same significant differences in total and LDL cholesterol between the groups at follow-up.

In conclusion, the significantly higher LDL levels in patients with AI treated with prednisolone vs hydrocortisone suggest that prednisolone should be used with great caution as hormone replacement therapy in this condition.
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[^1]: Patients with congenital adrenal hyperplasia were excluded.

[^2]: Data show mean (±[s.d.]{.smallcaps}) unless otherwise indicated.

[^3]: EU-AIR, European Adrenal Insufficiency Registry; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; [s.d.]{.smallcaps}, standard deviation.

[^4]: Data show mean (±[s.d.]{.smallcaps}) unless otherwise indicated.

[^5]: AI, adrenal insufficiency; EU-AIR, European Adrenal Insufficiency Registry; PAI, primary adrenal insufficiency; SAI, secondary adrenal insufficiency; [s.d.]{.smallcaps}, standard deviation.

[^6]: AI, adrenal insufficiency; EU-AIR, European Adrenal Insufficiency Registry.

[^7]: Data show mean (±[s.d.]{.smallcaps}) unless otherwise indicated.

[^8]: *P* = 0.013; \*\*\**P* = 0.003 (two-sample *t*-tests).

[^9]: AI, adrenal insufficiency; EU-AIR, European Adrenal Insufficiency Registry; [s.d.]{.smallcaps}, standard deviation.
